Douglas C. Bryant served as the CEO of QuidelOrtho Corporation, a prominent player in the diagnostic healthcare sector, from late 2022 until early 2024. He brought over 25 years of experience specifically in diagnostics and healthcare, having previously led various...

Douglas C. Bryant served as the CEO of QuidelOrtho Corporation, a prominent player in the diagnostic healthcare sector, from late 2022 until early 2024. He brought over 25 years of experience specifically in diagnostics and healthcare, having previously led various global operations at Abbott Laboratories, where he was known for his strategic oversight. Bryant took the reins at QuidelOrtho during a significant business transition, impacting company operations and growth strategies. Under his leadership, he aimed to align company values with stockholder interests and focused on meeting key financial performance metrics. In 2023, his overall compensation reached roughly $6.76 million, showing how performance-driven his role was, despite not earning a bonus that year due to unmet financial targets. Interestingly, Bryan had substantial equity awards within the company, indicating a strong belief in its future success. His diverse background made him a suitable leader, but his sudden termination after just over a year highlights the unpredictable nature of executive roles.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other QuidelOrtho Corporation CEOs

Q

Douglas C. Bryant

Ex-CEO of QuidelOrtho Corporation

Sector of Economy

Healthcare

CEO of QuidelOrtho Corporation for

1 year 2 months (Dec 2022 - Feb 2024)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Douglas C. Bryant

Holdings

See how much did Douglas C. Bryant make over time.

During his tenure, Douglas C. Bryant held significant stock options and restricted stock units in QuidelOrtho, accumulating over 700,000 stock options with an exercise price of $12.36, indicating a strong personal stake in the company's performance. His wealth fluctuated notably;...

During his tenure, Douglas C. Bryant held significant stock options and restricted stock units in QuidelOrtho, accumulating over 700,000 stock options with an exercise price of $12.36, indicating a strong personal stake in the company's performance. His wealth fluctuated notably; after performing exceptionally well in previous years, by 2023, he faced challenges that impacted his earnings, attributed to unmet revenue and EBITDA targets. In 2023, his vested stock was worth approximately $1.35 million, reflecting a decline compared to higher valuations in earlier years. The dynamics of his holdings and the company's stock performance underscored the complexities of leadership in a fast-paced industry.

Mar 18, 2025

Q

shares

QDEL @ $34.89

Total Stock Sold

$50.17M

QDEL

$50.17M

1,159,497 QDEL shares

What if they kept their stock?

If Douglas C. Bryant didn't sell their stock, today they would have:
Extra QDEL1,159,497 shares worth $178.15M.
This is 255.11% and $127.98M more than what they got when they sold the stock.

Charitable Transactions

QDEL

10,000 shares

QDEL

Recent Charitable Transactions

QDEL

10,000 shares

QDEL

Dec 21, 2017

Charity

Insider Trading

See recent insider trades of Douglas C. Bryant.

QDEL

4,911 shares

QDEL

Feb 1, 2024

Received

QDEL

18,854 shares

QDEL

Jan 31, 2024

Received

QDEL

1,461 shares

QDEL

Aug 24, 2023

Received

QDEL

15,180 shares

QDEL

Feb 23, 2023

Received

QDEL

9,501 shares

QDEL

Feb 11, 2023

Received

QDEL

22,515 shares

QDEL

Feb 3, 2023

Received

QDEL

7,875 shares

QDEL

Jan 31, 2023

Received

QDEL

1,460 shares

QDEL

Aug 24, 2022

Received

QDEL

505,926 shares

QDEL

May 27, 2022

Received

QDEL

3,795 shares

QDEL

Feb 3, 2022

Received

Compensation History

See how much did Douglas C. Bryant make over time.

In 2022, Douglas C. Bryant’s total compensation was recorded at $13.09 million, including a generous bonus, reflecting the company's growth and successful metrics at that time. However, in 2023, his compensation dropped to about $6.76 million, primarily due to disappointing financial outcomes where he did not receive a performance bonus after falling short of the Adjusted EBITDA targets. His salary alone was $1.06 million, supplemented by around $1.35 million in vested stock from previous performance-based RSUs. The varying levels of compensation demonstrate how executive pay can be both rewarding and volatile, directly tied to the organization's performance and Bryant's leadership effectiveness.

Year

2023

Total Compensation

$3.17M

Salary

$1.06M

Board Justification

The compensation program is designed to support the company's mission and values, aligning management's interests with those of stockholders while attracting and retaining high-quality executives.

Bonus

$556.96K

Board Justification

Under the 2023 Cash Incentive Plan, bonus payouts were weighted between the revenue targets and Adjusted EBITDA targets so that they were based 50% on achievement of revenue targets and 50% on achievement of Adjusted EBITDA targets. However, Mr. Bryant did not receive a bonus payout as the minimum target for Adjusted EBITDA was not met.

Other

$207.55K

Board Justification

Includes tax gross-ups, perquisites, and other personal benefits such as housing reimbursements and contributions to the 401(k) plan.

Restricted Stock

$1.35M(15.18K RSU)

Board Justification

Performance-based RSUs granted in February 2020 vested due to the achievement of a compounded annual growth rate target of 5.0% per year of GAAP total revenues over any three consecutive fiscal year period starting with the three-year period ended in 2022.

Performance Metrics

The performance metrics that determine the compensation include revenue targets and Adjusted EBITDA targets.

Other QuidelOrtho Corporation CEOs

Here are other CEOs of QuidelOrtho Corporation

Michael S. Iskra

Ex-CEO of QuidelOrtho Corporation

February 2024 - May 2024